
Ma Xiaoying
- Director of the Oncology Department at St. Stamford Modern Cancer Hospital Guangzhou
- Associate Chief Physician
- Over 20 years of clinical experience in oncology
Professional Memberships
- Member of the Specialized Committee on Medical Oncology, Chinese Anti-Cancer Association (CACA)
- Member of the Specialized Committee of Tumor Endoscopy
Areas of Expertise
Dr. Ma specializes in the diagnosis and treatment of a wide range of malignant tumors, particularly:
Cancer Types
- Digestive tract cancers
- Breast Cancer
- Lung Cancer
- Gynecological cancers
- Genitourinary cancers
Treatment Approaches
- Chemotherapy
- Endocrine therapy
- Molecular targeted therapy
- Immunotherapy
- Integrated treatment for advanced and refractory cancers
Minimally Invasive Techniques
Dr. Ma is highly experienced in advanced minimally invasive cancer therapies, including:
- Interventional therapy
- Radioactive seed implantation
- Cryotherapy
- Nanoknife technology
Clinical Philosophy
Dr. Ma advocates an integrative treatment approach that combines effective tumor control with the preservation of patients’ quality of life. She emphasizes precision minimally invasive therapies designed to reduce treatment-related discomfort, improve recovery, and prolong survival, especially for patients who are not suitable candidates for conventional surgery.
Academic Contributions
Dr. Ma has published multiple academic papers in professional medical journals, with research focusing on:
- Argon-helium cryoablation combined with chemotherapy for liver metastases from colorectal cancer
- Management of immunotherapy-related side effects, including SJS/TEN caused by PD-1 inhibitors
- Safety and short-term efficacy of combined therapies for esophageal cancer involving PD-1 inhibitors and targeted drugs
International Experience
Dr. Ma has treated more than 5,000 patients from Southeast Asia and actively participates in international medical collaborations. She is involved in cross-border academic and clinical exchanges with healthcare institutions in:
- Thailand
- Singapore
- Vietnam
- Malaysia
- Indonesia
Through these collaborations, she helps promote and share China’s minimally invasive cancer treatment standards and clinical protocols internationally.
